DUBLIN--(BUSINESS WIRE)--The "Meningioma - Pipeline Review, H2 2017" report has been added to Research and Markets' offering.
Meningioma - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Meningioma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Meningioma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Meningioma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Phase 0 and Preclinical stages are 8, 3, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 2 molecules, respectively.
Meningioma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Key Topics Covered:
- Introduction
- Meningioma - Overview
- Meningioma - Therapeutics Development
- Pipeline Overview
- Pipeline by Companies
- Pipeline by Universities/Institutes
- Products under Development by Companies
- Products under Development by Universities/Institutes
- Meningioma - Therapeutics Assessment
- Assessment by Target
- Assessment by Mechanism of Action
- Assessment by Route of Administration
- Assessment by Molecule Type
- Meningioma - Companies Involved in Therapeutics Development
- Arno Therapeutics Inc
- AstraZeneca Plc
- Boehringer Ingelheim GmbH
- Eli Lilly and Co
- Genentech Inc
- GlaxoSmithKline Plc
- Merck & Co Inc
- Merck KGaA
- Novartis AG
- Ono Pharmaceutical Co Ltd
- Pharma Mar SA
- Progenics Pharmaceuticals Inc
For more information about this report visit https://www.researchandmarkets.com/research/qqbdk3/meningioma?w=4
